On October 29, 2025, Eli Lilly announced a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico, aiming to support its growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology, and immunology[2][4]. The facility will manufacture orforglipron, Lilly's first oral GLP-1 receptor agonist, which is expected to be submitted for global regulatory approval for obesity by the end of 2025[4]. LLY shares are trading higher at $827.90 (+0.95%) as of midday, likely reflecting positive investor sentiment toward the expansion and anticipation of the upcoming earnings report on October 30, 2025[1][2]. Broader market gains and optimism ahead of the Fed rate decision may also be contributing to the stock's upward movement.